Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk | Zendy

Peter M.A. Calverley | Zendy; Julie A. Anderson | Zendy; Robert D. Brook | Zendy; Courtney Crim | Zendy; Natacha Gallot | Zendy; Sally Kilbride | Zendy; Fernando J. Martínez | Zendy; Julie Yates | Zendy; David E. Newby | Zendy; Jørgen Vestbo | Zendy; Robert A. Wise | Zendy; Bartolomé R. Celli | Zendy

Open Access

Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk

Author(s) -

Peter M.A. Calverley,

Julie A. Anderson,

Robert D. Brook,

Courtney Crim,

Natacha Gallot,

Sally Kilbride,

Fernando J. Martínez,

Julie Yates,

David E. Newby,

Jørgen Vestbo,

Robert A. Wise,

Bartolomé R. Celli

Publication year - 2017

Publication title -

american journal of respiratory and critical care medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.272

H-Index - 374

eISSN - 1535-4970

pISSN - 1073-449X

DOI - 10.1164/rccm.201610-2086oc

Subject(s) - medicine , copd , fluticasone propionate , placebo , spirometry , body mass index , pulmonary function testing , corticosteroid , cardiology , asthma , alternative medicine , pathology

Many patients with chronic obstructive pulmonary disease (COPD) have an accelerated loss of lung function. It is unclear whether drug treatment can modify this in patients with moderately severe disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research